Characteristics of included studies
| Study | Sex/Species/Strain/Weight | SCI/Treat (n) | Model of injury | Interval time injury to treat (day) | Transplantation location | GABAergic cell type | Cell type | Immunosuppressive/Antibiotic/Blinding |
Transplantation methods cell/Type graft |
FU (day) |
|---|---|---|---|---|---|---|---|---|---|---|
| Bráz et al., 2012 [22] | Male/Mice/C57BL6/J/6-8 week | 13/10 | SNI | 7 | Dorsal horn of lumbar spinal cord | GABAergic MGE interneurons | Intrinsic GABAergic cell | No/No/Yes | Intraspinal: 5 × 104 cell/Allograft | 28 |
| Bráz et al., 2015 [23] | Male/Mice/C57BL6/J/8 weeks | 5/5 | Paclitaxel induce pain | 7 | Dorsal horn of lumbar spinal cord | GABAergic MGE interneurons | Intrinsic GABAergic cell | No/No/Yes | Intraspinal: 5 × 104 cell/Allograft | 28 |
| Eaton et al., 1999 [25] | Female/Rat/Wistar/180 g | 14/14 | CCI | 7 | L1 | 33G10.17 | Genetically modified cell | No/No/No | Intraspinal: 1 × 106 cell/Allograft | 56 |
| Eaton et al., 2012 [24] | Female/Rat/NR/Adult | 15/15 | Streptozotocin induce neuropathic pain, CCI, excitotoxic spinal cord injury | 14 | Subarachnoid space of dorsal horn | Viable hNT2.17 cells | Genetically modified cell | Yes/Yes/Yes | Intrathecal: 1 × 106 cell/Xenograft | 56 |
| Etlin et al., 2016 [26] | Male/Mice/C57BL6/J/6-8 weeks | 10/10 | SNI | 3 | Dorsal horn on one side of the spinal | GABAergic interneurons from the mouse medial ganglionic eminence | Intrinsic GABAergic cell | No/No/Yes | Intraspinal: 5 × 104 cell/Allograft | 21 |
| Hwang et al., 2016 [16] | NR/Rat/SD/Adult | 7/7 | SCI contusion injury | 21 | Intrathecal injection | mESC-NPCs | Intrinsic GABAergic cell | No/No/Yes | Intrathecal: 1 × 106 cell/Allograft | 56 |
| Jergova et al., 2012 [27] | Male/Rat/SD/140-160 g | 10/10 | CCI | 7 | L3-L4 | GABAergic NPCs | Genetically modified cell | No/No/Yes | Intraspinal: 3 × 105 cell/Allograft | 35 |
| Jergova et al., 2016 [15] | Male/Rat/SD/140-160 g | 6/6 | CCI | 7 | L3-L4 | GABAergic NPCs | Genetically modified cell | No/No/Yes | Intraspinal: 5 × 105 cell/Allograft | 35 |
| Juarez-Salinas et al., 2019 [28] | Male/Mice/C57BL6/J/6-8 weeks | 7/9 | Paclitaxel induce pain | 7 | Anterior cingulate cortex | GABAergic interneurons from the mouse medial ganglionic eminence | Intrinsic GABAergic cell | No/No/Yes | Intracranial; 5 × 104 cell; Allograft | 30 |
| Kim et al., 2010 [29] | Male/Rat/SD/170-200 g | 76/40 | Hemisection injury | 14 | T13-L1 | ESC-derived GABAergic cell | Stem cell derived | No/No/Yes | Intraspinal: 5 × 105 cell/Xenograft | 70 |
| Manion et al., 2020 [32] | Male/Mice/NOD prkdSCID/10 weeks | 21/29 | SNI | 7 | L1 | ATCC-BXS0116 hiPSC | Genetically modified cell | No/Yes/Yes | Intraspinal: 2 × 105 cell/Xenograft | 63 |
| Mukhida et al., 2007 [30] | Female/Rat/Wistar/175-200 g | 5/7 | L5-L6 nerve ligation | 10 | L1 | NPC-derived GABAergic cells | Stem cell derived | NR/NR/Yes | Intraspinal: 2 × 105 cell/Xenograft | 42 |
| Vaysse et al., 2011 [31] | Male/Rat/SD/225-250 g | 8/8 | CCI | 14 | Intrathecal injection | hNT2.17 | Genetically modified cell | Yes/No/No | Intrathecal: 1 × 106 cell/Xenograft | 42 |
SCI: spinal cord injury, FU: follow up duration, NR: not reported, SD: Sprague–Dawley, SNI: spared nerve injury, CCI: chronic constriction injury of the sciatic nerve, MGE: medial ganglionic eminence, mESC-NPCs: mouse embryonic stem cell–derived neural precursor cells, NPC: neural progenitor cells, ESC: embryonic stem cells, hiPSC: human induced pluripotent stem cells.
aBlinding of outcome assessor.